MindMed reports a Q2 2021 loss of $36 million. Current cash on hand of $157 million.
MindMed reports a Q2 2021 loss of $36 million. Current cash on hand of $157 million.
ATAI's newest research partner, Revixia Life Sciences, is seeking to treat depression and substance abuse with Salvinorin A, a lesser-known psychedelic used by indigenous peoples.
The Mental Health Crisis is now a mental health pandemic. Is access to psychedelic medicine the world's largest human rights issue?
Wesana Health announces the commencement of pre-clinical psychedelics research for Traumatic Brain Injury.
Compass Pathways reports a Q2 loss of $17.5 million and announces raising $154.8 million in a new financing in May.
Two billion people have treatable mental health disorders. Where existing therapies are merely inadequate crutches, psychedelic drugs can produce cures.
Psychedelic Stock Watch compares and contrasts the drug development opportunities with psychedelic drugs (and psychedelic drug stocks).
MINDCURE announces that renowned human rights activist, Jerry White, has joined the company as an advisor. Winner of the Nobel Peace Prize, White will help MINDCURE revolutionize mental health.
Atai Life Sciences announces the launch of a new intranasal drug delivery system, InnarisBio, based on sol-gel technology.
MindMed is preparing to commence a Phase I clinical trial on the safety/tolerance of intravenous DMT.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now